HomeCompareVECT vs QYLD

VECT vs QYLD: Dividend Comparison 2026

VECT yields 11.86% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VECT wins by $18.3K in total portfolio value
10 years
VECT
VECT
● Live price
11.86%
Share price
$16.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.7K
Annual income
$2,485.28
Full VECT calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — VECT vs QYLD

📍 VECT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVECTQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VECT + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VECT pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VECT
Annual income on $10K today (after 15% tax)
$1,007.71/yr
After 10yr DRIP, annual income (after tax)
$2,112.49/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $2,697.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VECT + QYLD for your $10,000?

VECT: 50%QYLD: 50%
100% QYLD50/50100% VECT
Portfolio after 10yr
$34.6K
Annual income
$4,072.30/yr
Blended yield
11.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VECT right now

VECT
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$18.00
+6.7% upside vs current
Range: $18.00 — $18.00
Altman Z
13.9
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VECT buys
0
QYLD buys
0
No recent congressional trades found for VECT or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVECTQYLD
Forward yield11.86%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$43.7K$25.4K
Annual income after 10y$2,485.28$5,659.31
Total dividends collected$18.2K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: VECT vs QYLD ($10,000, DRIP)

YearVECT PortfolioVECT Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$11,886$1,185.54$10,352$1,192.36+$1.5KVECT
2$14,034$1,316.89$10,830$1,347.57+$3.2KVECT
3$16,470$1,453.25$11,460$1,539.07+$5.0KVECT
4$19,217$1,593.89$12,275$1,777.84+$6.9KVECT
5$22,300$1,738.05$13,323$2,078.95+$9.0KVECT
6$25,746$1,884.96$14,667$2,463.34+$11.1KVECT
7$29,582$2,033.87$16,396$2,960.57+$13.2KVECT
8$33,837$2,184.03$18,631$3,612.97+$15.2KVECT
9$38,540$2,334.73$21,548$4,482.15+$17.0KVECT
10$43,723$2,485.28$25,398$5,659.31+$18.3KVECT

VECT vs QYLD: Complete Analysis 2026

VECTStock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Full VECT Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this VECT vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VECT vs SCHDVECT vs JEPIVECT vs OVECT vs KOVECT vs MAINVECT vs XYLDVECT vs JEPQVECT vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.